Thuenthkin Anbelos

Pharmacy Technician Certification Board (PTCB) Supports Florida's New Patient Safety Solution

The Pharmacy Technician Certification Board (PTCB), the leading national program that has certified more than 300,000 pharmacy technicians, supports and congratulates the Florida House of Representatives and Governor Charlie Crist for passing legislation requiring new standards for pharmacy technicians. The new Florida legislation takes a progressive step toward increasing patient safety for consumers. The legislation will ensure pharmacy technicians meet key requirements for training, certification and registration.

Washington, D.C. - June 27, 2008 -- The Pharmacy Technician Certification Board (PTCB) (http://www.ptcb.org/), the leading national program that has certified more than 300,000 pharmacy technicians, is pleased to support and congratulate the Florida Legislature for passing SB 1360 and Governor Charlie Crist for signing it into law, requiring new standards for pharmacy technicians. Tireless advocacy efforts for the passage of this critical patient safety legislation and its final approval by Governor Crist were spearheaded by the Florida Society of Health-System Pharmacists (FSHP) and the Florida Pharmacy Association (FPA).

The new Florida legislation takes a progressive step toward increasing patient safety for consumers. By passing this legislation without amendment, and signing it into law, the Florida state legislature and governor will ensure pharmacy technicians meet key requirements for training, certification and registration. PTCB is proud to have certified 15,000 pharmacy technicians in Florida to date and looks forward to working with more pharmacy technicians and their employers.

"Florida's new pharmacy technician standards are an important patient safety solution for consumers in the Sunshine State and Governor Crist and the state's legislators should be applauded," said PTCB Executive Director and CEO Melissa Murer Corrigan. "To meet these new state standards, PTCB is looking forward to continued work with pharmacy technicians and significant employers of Florida's pharmacy technicians such as Walgreen's, CVS, Publix, Target, the U.S. military, multiple health-systems and independent pharmacists in communities across the state. Several of these employers presently support and endorse PTCB across the United States."

The landmark piece of Florida legislation (SB 1360) contributes to raising the bar for states across the country by providing an example of the high standards needed for pharmacy technicians. The more than 40,000 pharmacy technicians currently working in Florida will be required to register with the Florida Board of Pharmacy by 2010. In 2011, they will need to either complete a board-approved training program with 1,500 hours of work as a technician under a Florida licensed pharmacist, or be certified (https://www.ptcb.org/AM/Template.cfm?Section=Guidebook_to_Certification&Template=/CM/HTMLDisplay.cfm&ContentID=2952) by a program accredited by the National Commission for Certifying Agencies (NCCA). PTCB is the pioneer in certifying pharmacy technicians (https://www.ptcb.org/AM/Template.cfm?Section=Learn&Template=/CM/ContentDisplay.cfm&ContentID=1384) and is accredited by the NCCA. PTCB's certification program has been included in regulations by more than 30 state boards of pharmacy. Through its strategic partnership with Pearson VUE, PTCB is able to offer highly scalable computer-based testing through the world's largest network of testing centers.

Studies show without a doubt that Americans support a standard of excellence for pharmacy technicians. A recent poll commissioned by PTCB confirms that 91% of American consumers support strong regulations across the country to protect patient safety by requiring that pharmacy technicians are trained and certified. While states like Florida reflect this growing need for action, almost twenty other states still have no requirement for certification. Clearly, consumers are relying on state boards of pharmacy to protect them and enact strong requirements such as Florida's for pharmacy technicians.

About the Pharmacy Technician Certification Board (PTCB) (http://www.ptcb.org/)

PTCB was established in January 1995 and is governed by five pharmacy organizations - the American Pharmacists Association (APhA), the American Society of Health-System Pharmacists (ASHP), the Illinois Council of Health-System Pharmacists (ICHP), the Michigan Pharmacists Association (MPA) and the National Association of Boards of Pharmacy (NABP). Since PTCB's inception, PTCB has certified over 300,000 pharmacy technicians through the examination and transfer process. PTCB's certification program is accredited by the National Commission for Certifying Agencies (NCCA). The goal of the PTCB national certification program is to enable pharmacy technicians to work more effectively with pharmacists to offer safe and effective patient care and service. PTCB contracts with Pearson VUE, the industry's technology leader, as its computer-based testing vendor. PTCB draws upon the experience and expertise of its 13-year partner, Professional Examination Service (PES) for test development.

Contact Information
Mark Franco
The Pharmacy Technician Certification Board
http://www.ptcb.org
202-429-7508
202-828-9767

# posted by Thuenthkin Anbelos : 9:14 PM  0 Comments

InterventionTreatment.com Launches Suboxone Treatment Program

LOS ANGELES-- June 27, 2008 --Intervention Treatment announced today that it has launched a suboxone treatment program. The program will be used to increase Intervention Treatment's Global mission of providing Intervention and Treatment resources to those affected by alcohol and drug addiction. According to Dr. Jason Schiffman, Chief Medical Officer for Intervention Treatment, "There is a large, poorly met demand for outpatient, office-based treatment of opiate dependence and the addition of the suboxone treatment program to Intervention Treatment's array of alcohol and drug addiction related services will be a great tool for patients and their families."

Intervention Treatment is currently one of the fastest growing online resources for those affected by drug and alcohol addiction. The new Suboxone Treatment program is designed to help those affected by opiate addiction.

About Suboxone:

Suboxone is the first drug approved by the FDA for opiate dependence treatment in office based settings. This means that patients addicted to opiates may now choose to receive opiate-based treatment as an outpatient instead of in a hospital setting. Patients are evaluated and treated during office visits and receive a prescription for suboxone which they may fill at any pharmacy. Suboxone is comprised of two separate medications: buprenorphine and naloxone. Buprenorphine is a partial opiate agonist, meaning its opiate effects are significantly reduced compared to that of full opiate agonists, such as vicodin or heroin. The naloxone in suboxone is not appreciably absorbed from the digestive track when suboxone is taken orally and is in place to prevent the misuse of suboxone by injection drug users. The combination of these two medications leads to suboxone's effectiveness in treating opiate dependence.

About Suboxone Treatment:

Suboxone treatment differs significantly from standard opiate dependence treatment programs. Traditionally, opiate addicts undergoing medical detoxification have been administered either methadone or a combination of drugs, each targeting a symptom of withdrawal. The latter approach usually must take place in an inpatient setting in order to be done safely, while methadone treatment requires a patient to visit a clinic on a daily basis to receive a prescribed dose. Suboxone treatment differs from these treatments in several important ways. Firstly, a prescription for suboxone can be obtained at a specially licensed physician's office and filled at any pharmacy. This means the patient does not need to be admitted to a hospital or make daily visits to a methadone clinic in order to receive their medication. Secondly, because suboxone is a mixture of naloxone and buprenorphine, a partial opiate agonist with a long duration of action, the potential for abuse and overdose are much less than with methadone. Thirdly, because buprenorphine is a partial opiate agonist, suboxone may be easier to taper off of than full opiate agonists like methadone.

About Intervention Treatment

Intervention Treatment, formed in 2007, is an internet resource offering help to those affected by drug and alcohol addiction. Intervention Treatment provides referrals to drug and alcohol rehabs, intervention services, suboxone treatment referrals, and general information regarding addiction and treatment.

Safe Harbor Statement

This press release contains statements that may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of the Company, and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contacts

Intervention Treatment
William Donovan, Co-Founder, 949-267-4113
bj@interventiontreatment.com
www.interventiontreatment.com

# posted by Thuenthkin Anbelos : 8:51 PM  0 Comments

Dairyland Healthcare Solutions' Physician Practice Documentation Receives 2007 CCHIT Certification

Software Complies with 100 Percent of Updated 2007 Certification Criteria

GLENWOOD, Minn.-- June 18, 2008 --The Certification Commission for Healthcare Information Technology (CCHIT®) today announced that Dairyland Healthcare Solutions' Physician Practice Documentation (PPD), Version 9.0.0 is CCHIT Certified®, and meets the Commission's ambulatory electronic health record (EHR) criteria for 2007. Ambulatory EHRs are designed for physician offices and clinics where most Americans get their healthcare. CCHIT - an independent, nonprofit organization - is the Recognized Certification Body in the United States for certifying health information technology products.

In the second year of the program's operation, the criteria and testing have been significantly enhanced. The Commission added 96 criteria to the 151 original requirements from last year. As a CCHIT Certified product has been tested and passed inspection of 100 percent of a set of updated criteria for functionality, interoperability and security.

"For 2007, the Commission raised the bar from the previous year's criteria. Ambulatory EHRs now must include electronic prescribing, demonstrate an ability to receive lab results, and show enhanced patient safety, quality, and security features," said Mark Leavitt, M.D., Ph.D., chair, CCHIT. "Investment in 2007 certified ambulatory EHRs gives providers even more powerful tools to improve quality, safety and efficiency while protecting the privacy of health information."

The CCHIT Certified mark - a "seal of approval" for EHR products - provides the first consensus-based, government-recognized benchmark for ambulatory EHR products. By looking to products with the CCHIT Certified seal, physicians and other providers can reduce their risk in selecting an EHR product, allowing them to focus their evaluation on the special needs of their practices.

"We are delighted to receive CCHIT certification," said James Burgess, CEO of Dairyland. "The CCHIT review process is rigorous and essential to ensuring that technologies carrying this important certification meet the highest safety and quality standards. We are pleased that CCHIT recognizes Dairyland's high standards," he added.

CCHIT's certification compliance criteria and its design for a certification inspection process have been thoroughly researched, taking into account the state of the art of EHRs and available standards, and comparing certification processes in other industries and other countries. The inspection process is based on real-life medical scenarios designed to test products rigorously against the clinical needs of providers and the quality and safety needs of healthcare consumers and payers. One script, for example, recreates a scenario of an elderly man with poorly controlled diabetes, hypertension and other chronic conditions in order to test EHR functions such as potential adverse drug reactions, disease management and treatment plans.

About Dairyland Healthcare Solutions

Dairyland Healthcare Solutions is an award-winning healthcare information systems company that links essential information between small community hospitals and their healthcare delivery and business networks. Dairyland enables its hospital partners to deliver the highest level of patient care by providing the information infrastructure required to operate effectively in the dynamic and complex healthcare delivery environment. For almost three decades, Dairyland has partnered with leading community hospitals to help them improve efficiencies, enhance profitability and ensure patient safety by providing solutions to manage, integrate and access key financial, clinical and patient information. Dairyland is the only company to be awarded three consecutive "Best in KLAS" ratings in the Community Hospital Information Systems category. To learn more, visit: http://www.dhsnet.com.

About CCHIT

The Certification Commission for Healthcare Information Technology (CCHIT®) is an independent, nonprofit organization that has been named by the federal government as the Recognized Certification Body for health information technology. Its mission is to accelerate the adoption of health information technology by creating a credible, sustainable certification program. The certification requirements are based on widely accepted industry standards and involve the work of hundreds of expert volunteers and input from a variety of stakeholders throughout the health care industry. More information on CCHIT and CCHIT Certified® products is available at www.cchit.org.

"CCHIT®" and "CCHIT Certified®" are service marks of the Certification Commission for Healthcare Information Technology.

Contacts

Dairyland Healthcare Solutions
Tracey Schroeder, 612-787-3125
VP Marketing & Communications
tracey.schroeder@dhsnet.com
or
CCHIT
Sue Reber, 503-703-0813
sreber@cchit.org

# posted by Thuenthkin Anbelos : 3:05 PM  0 Comments

Two-Year Clinical Trial Findings Show Significant and Persistent Reduction in Blood Pressure with CVRx® Rheos® Hypertension Therapy

Data Presented at Hypertension Berlin 2008 Congress; Pivotal Rheos Trial in Progress
Hypertension Berlin 2008

MINNEAPOLIS & BERLIN-- June 18, 2008 --The first available two-year data from the European clinical trial evaluating the Rheos® Hypertension (HT) System were presented today at Hypertension Berlin 2008. Developed by U.S.-based CVRx, Inc., the Rheos HT System is the only implantable medical device designed to control hypertension, or high blood pressure. Worldwide, hypertension is a leading and growing cause of heart and kidney disease, stroke and death. The Rheos HT System could provide a new treatment option for the millions of people who cannot control their hypertension with medications. The device activates the body's own system for regulating blood pressure.

"We are excited to see a sustained reduction in blood pressure after two years of Rheos HT Therapy - a major milestone in the evaluation of our novel treatment approach," said Nadim Yared, CVRx president and chief executive officer. "Hypertension is a complex condition, affecting multiple physiological functions. The early data on improved heart function and preserved kidney function also presented at this conference are encouraging, and we are hopeful Rheos HT Therapy may help prevent serious, costly conditions related to hypertension. Our Rheos Pivotal trial is assessing the safety and clinical efficacy of Rheos HT System and is well underway."

The clinical data from the Device-Based Therapy of Hypertension (DEBuT-HT) study (Abstract No. OS17/3) were presented at Hypertension Berlin 2008, a joint congress held in Berlin of the 18th Scientific Meeting of the European Society of Hypertension and the 22nd Scientific Meeting of the International Society of Hypertension. Of the 45 patients enrolled in this study, 16 patients from four European centers have completed two years of Rheos HT Therapy. Blood pressure measurements were taken in the clinic and after two years showed:

    * Systolic blood pressure was reduced by an average of 35 mmHg (191 mmHg vs.156 mmHg); and
    * Diastolic blood pressure was reduced by an average of 24 mmHg (116 mmHg vs. 92 mmHg).

Similar results were found at three months and one year of Rheos HT Therapy. Patients remained on background medical therapy during the trial. During the two-year study period, the average number of antihypertensive medications remained stable.

A drop in systolic blood pressure of at least 20 mmHg was achieved in 12 of the 16 patients (75 percent). The Rheos implants were well tolerated, and there were no unanticipated adverse events related to the system or procedure. Further information on these study results can be found on the CVRx Web site at www.cvrx.com.

Peter de Leeuw, professor of medicine and hypertension at the University of Maastricht in The Netherlands, is the leading enroller in the DEBuT-HT study. The 16 patients included in the two-year results were from the following clinical trial sites: the University Hospital Maastricht and Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; University Hospital, Inselspital Bern, Bern, Switzerland; Humboldt University Charité Campus Buch, Berlin; and Heart and Diabetes Center North Rhine Westphalia, Bad Oeynhausen, Germany.

Additional Rheos Data Presented at Hypertension 2008

Additional data from the DEBuT-HT study and U.S. Rheos feasibility study were presented in two poster sessions at Hypertension 2008. These studies showed early signs that the Rheos HT System can improve heart function and preserve kidney function.

    * Heart function was notably improved among the 16 patients who completed one year of Rheos HT Therapy (Abstract No. PS33/THU/24). Blood pressure was reduced significantly, and left ventricular hypertrophy (LVH) significantly regressed. LVH, a process in which the heart becomes enlarged and does not work efficiently, increases the risk of heart attacks, heart failure and sudden cardiac death and regression of LVH reduces these risks.
    * The University of Maastricht studied the effects of the Rheos HT Therapy on kidney function (Abstract No. PS32/WED/63) among their 12 patients who received therapy for one year. In this group, the Rheos HT Therapy was shown to help preserve kidney function over this time period. High blood pressure increases the risk and progression of kidney disease.

U.S. Rheos Pivotal Trial in Progress

CVRx received investigational device exemption (IDE) approval from the FDA to begin the Rheos Pivotal Trial to evaluate the safety and effectiveness of the Rheos HT System. The trial is enrolling 300 patients at multiple clinical sites in the United States and in Europe. Prospective patients can call (888) 8BP-RISK (827-7475) or visit www.bloodpressuretrial.com, to learn more about the clinical trial.

The Rheos HT System: Working with the Body's Own Mechanisms

The Rheos HT System uses CVRx patented Baroreflex Activation TherapyT (BATT) technology that is designed to electrically activate the carotid baroceptors, the body's natural blood pressure sensors. When the baroreceptors are activated, signals are sent through neural pathways to the brain and interpreted as a rise in blood pressure. The brain works to counteract this perceived rise in blood pressure by sending signals to other parts of the body (heart, blood vessels and kidneys) to lower high blood pressure.

The Rheos HT System includes the following components:

    * A small pulse generator that is implanted under the collar bone;
    * Two thin lead wires that are implanted at the left and right carotid arteries and connect to the pulse generator; and
    * The Rheos Programmer System, an external device used by doctors to non-invasively regulate the activation energy from the generator to the lead wires.

About Hypertension

Hypertension causes an estimated one in eight deaths worldwide.1 In the United States alone, high blood pressure affects approximately 73 million people.1 Approximately 25 percent of people with hypertension cannot control their high blood pressure, despite the use of multiple medications. 2, 3 Each incremental increase of 20 mmHg in systolic blood pressure or 10 mmHg in diastolic blood pressure above normal levels is associated with a two-fold increase in death rates from stroke, coronary heart disease and other vascular causes.

Editor's Note: Blood pressure is typically recorded as two numbers - the systolic pressure (top number) over the diastolic pressure (bottom number). The systolic pressure is the pressure of blood in the vessels when the heart contracts. Diastolic pressure is the pressure of the blood between heartbeats, when the heart is at rest and is refilling.

About CVRx, Inc.

CVRx, Inc., is a private company founded in 2001 and headquartered in Minneapolis, Minnesota U.S.A. Its senior management and technical teams have many years of experience commercializing implantable medical devices. For more information, visit www.cvrx.com.

1 Heart Disease and Stroke Statistics. American Heart Association - 2008 Update.

2 Lancet 2002;360:1903-1913.

3 JAMA 2003;289:2560-2572.

CAUTION: CVRx Rheos System is an investigational device and is limited by Federal (or United States) law to investigational use only.

CVRx, Rheos, Baroreflex Activation Therapy and BAT are trademarks of CVRx, Inc.

© CVRx, Inc. 2008. All rights reserved.

Contacts

CVRx
John Brintnall, 763-416-2853
Chief Financial Officer
jbrintnall@cvrx.com
or
Mary McGrory-Usset, 651-308-8225
Corporate Communications
mmcgroryusset@comcast.net
or
Padilla Speer Beardsley:
Nancy Johnson, 612-455-1745, 612-812-7568 cell
njohnson@psbpr.com
or
Nick Banovetz, 612-455-1705, 651-815-5999 cell
nbanovetz@psbpr.com

# posted by Thuenthkin Anbelos : 9:36 AM  0 Comments

Large Louisiana Nursing Home will use Web-based Referral Management System™ to optimize and manage patient referral and placement. Patient Placement Systems announced today that Belle Maison Nursing Home, a 179-bed nursing home and retirement care facility in Hammond, Louisiana, has signed a three-year contract to use the Patient Placement Referral Management System.

Atlanta, GA  -  January 22, 2008 -- Patient Placement Systems announced today that Belle Maison Nursing Home, a 179-bed nursing home and retirement care facility in Hammond, Louisiana, has signed a three-year contract to use the Patient Placement Referral Management System.

The Patient Placement Referral Management System enables nursing homes, home health agencies, hospices, rehabilitation facilities and other extended care organizations to automate the entire referral management process, efficiently tracking and managing all inbound patient referrals, as well as their associated medical records. Automating this traditionally manual and fax-based process gives facilities a unique opportunity to increase patient placements, better serve patients and referring facilities, enhance productivity, and gain data for better decision-making about their referral management process.

Belle Maison Nursing Home, winner of the 2007 Nursing Home Quality Initiative Achievement Award from the Louisiana Health Care Review, constantly seeks ways to improve processes and enhance quality of care. "The Referral Management System will not only help us place more patients, more efficiently; it will also give us a competitive advantage," says Administrator Paul Guitreau. Guitreau indicates that manual referral tracking processes can result in errors, problems and delays. The Referral Management System will enable Belle Maison to respond more quickly to referral sources, enhance staff productivity and have richer data for analysis and decision-making.

"With the Referral Management System, Belle Maison will save significant time and replace multiple manual processes. Furthermore, they'll have a new level of business intelligence regarding referral source, payor mix and other critical data," says Eric Christ, president of Patient Placement Systems. "And because the system was live in less than a week, they'll see benefits very quickly."
 
 The Referral Management System improves visibility and efficiency by capturing all inbound patient referrals and medical documents through a HIPAA-compliant Web-based application, effectively eliminating the need for an admissions team fax machine. The Referral Management System includes reporting and analysis at every level - by location, by referral source, by user, by line of business, by payor, and more.

About Patient Placement Systems:
Patient Placement Systems automates the referral process at continuing care providers, hospitals, and payors. The Patient Placement Referral Management System and Discharge Referral System improve information flow and communication so each party involved in patient referral has the information they need, when they need it. Patient Placement Systems is a member of the Jackson Healthcare Solutions family of companies. For more information about Patient Placement Systems, visit www.PatientPlacement.com or call 877-748-6656.


Press Contact: Monique Ervin
Company Name: Patient Placement Systems
Phone: 877-748-6656
Website: www.PatientPlacement.com

# posted by Thuenthkin Anbelos : 3:38 PM  0 Comments

Johns Hopkins Health Alerts reports on the latest findings on the causes of rheumatoid arthritis, and how it can affect your heart, leading to increased risk of heart attack and stroke, and thus decreased life expectancy.

New York, NY  - March 18, 2008 -- In a recent issue of The Johns Hopkins Arthritis Bulletin, Johns Hopkins specialists reported on the latest research regarding the link between rheumatoid arthritis and heart health.

With rheumatoid arthritis, the inflammation that damages joints also takes a toll on the heart. Johns Hopkins specialists offer bottom line advice on how to adopt a heart-healthy lifestyle to combat the effects of rheumatoid arthritis (RA) and its accompanying inflammation.

BEING HEART-SMART WITH RA
People with rheumatoid arthritis understandably focus on caring for their joints. But their most serious health risk involves their heart.

Compared to the general population, rheumatoid arthritis patients have a significantly increased risk of heart attack and stroke, and a shorter life expectancy.

RA AND YOUR HEART: THE RISKS
Here are some of the findings from recent studies about the link between rheumatoid arthritis and heart disease:

* Heart attacks are twice as common among women with rheumatoid arthritis as among those without the disease.
* Atherosclerosis ("hardening of the arteries") starts early and progresses more rapidly in people with rheumatoid arthritis.
* Carotid artery blockages (a risk factor for stroke) are three times more common in people with rheumatoid arthritis than in people without the disease (44% vs. 15%).
* Cardiovascular events, such as heart attack and stroke, occur about 10 years earlier in people with rheumatoid arthritis.
* Mortality is higher among rheumatoid arthritis patients after a first heart attack.
* Blood vessel damage is often already apparent at the time of rheumatoid arthritis diagnosis.
* Heart attacks in rheumatoid arthritis patients are more likely to be silent or to occur without the typical symptoms, and they more often result in sudden cardiac death.
* Congestive heart failure (weakening of the heart's pumping ability) is more common among people with rheumatoid arthritis.
Researchers have identified several links between rheumatoid arthritis and cardiovascular disease. Inflammation is believed to be the most important of these.

THE ROLE OF INFLAMMATION IN ATHEROSCLEROSIS
Cardiologists now understand that inflammation plays a crucial role in the onset of atherosclerosis. They believe that an injury to the inner lining of the arteries (the endothelium) triggers an immune response, sending immune system cells rushing to repair the damage.

THE EFFECTS OF CHRONIC INFLAMMATION ON YOUR ARTERIES
But in chronic inflammatory states such as rheumatoid arthritis, the immune response doesn't shut off after the injury heals. The accumulating immune system cells attract deposits of cholesterol, blood platelets, cellular debris, and calcium, which clump together to form plaque.

As plaque deposits grow, they restrict blood flow through the artery. If the plaque ruptures, clots can break away and travel to the heart or brain, where they may cause a heart attack or a stroke.

BOTTOM LINE ADVICE: WHAT CAN YOU DO TO STAY HEART-SMART EVEN IF YOU HAVE RHEUMATOID ARTHRITIS
The relationship between rheumatoid arthritis and the heart is complex, and rheumatologists still have a great deal to learn about how to reduce the risk of cardiovascular disease among people who have rheumatoid arthritis.

For now, it's important to do everything possible to reduce the traditional risk factors for heart disease and stroke:
smoking, obesity, a sedentary lifestyle, high blood pressure, high cholesterol, and diabetes.

Getting regular exercise and losing extra pounds (even a 5-10% weight reduction is beneficial) will help your joints as well as your heart. Monitor your blood pressure and have your cholesterol levels checked regularly.

Also, ask your physician about the possibility of taking a low-dose aspirin each day to reduce your risk of cardiovascular disease.

In addition, the cholesterol-lowering medications known as statins--atorvastatin (Lipitor) and others--not only help the heart, but also have modest beneficial effects on rheumatoid arthritis-related inflammation. If your doctor hasn't already suggested a statin drug for your heart health, you might ask about it.

This information is exceprted from The Johns Hopkins Arthritis Bulletin:
Johns Hopkins Arthritis Bulletin

Johns Hopkins Health Alerts publishes free email newsletters on arthritis at:
Johns Hopkins Arthritis Health Alerts

And on heart health at:
Johns Hopkins Heart Health Alerts

For the latest research on Heart Health and Heart Attack Prevention, see the new 2008 Johns Hopkins White Paper: Heart Attack Prevention at: Johns Hopkins White Paper Heart Attack Prevention

To get a copy of the free special report "Johns Hopkins 7 Keys to Reduce Cholesterol," please visit:
Johns Hopkins 7 Keys to Reduce Cholesterol

Press Contact: JOAN MULLALLY
Company Name: Johns Hopkins Health Alerts
Phone: 917-640-4362
Website: http://www.johnshopkinshealthalerts.com

# posted by Thuenthkin Anbelos : 3:20 PM  0 Comments

Recent hires in management, creative development, production and sales have the company ready to soar to new heights.

Cape Coral, Florida - December 13 -- Healthcare News Network (www.healthcarenewsnetwork.com) is expanding their team. Recent hires in management, creative development, production and sales have the company ready to soar to new heights. 

Joann Ellis has been named General Manager and brings with her a diverse background to expand the network. Joann graduated Magna Cum Laude from The Ohio State University with a Masters degree in Quantitative Analysis and Measurement. Joann's background experience includes consulting for Ohio Collaborative, a group specializing in research for state agencies and writing briefs for the Ohio Senate and lobbying groups, as well as Titan Financial Group in Atlanta where she created and facilitated employee training programs and developed models for risk management.

Gregory Bush, Healthcare News Network CFO, is responsible for the financial reporting and technical infrastructure of the network. Greg brings with him over 20 years of management, financial and systems experience from both private and public companies, including Colorworks, Morgenthau and Bush Industries. A graduate of State University of New York Fredonia, Greg holds a degree in Business Management and Computer Engineering.

Juan Andres Rodriguez, named HNN's Creative Director, is a talented graphic artist and develops the feel of the network. A Cum Laude graduate of Eastern Connecticut State University, Juan has a passion for life, well-being and happiness which translates into the mission of the Healthcare News Network. Juan has worked for such advertising agencies as Leo Burnett and Grupo Z in Mexico and was a part of the launch of Zombra, a below-the-line advertising agency also based out of Mexico. Juan is part owner of Baja Design Studios in Baja California, Mexico, a freelance design studio specializing in the image and promotion of new businesses throughout the area.

Michael Shapiro, VP Director of Programming, is responsible for the content and substance of the network. He is committed to acquiring video material and public service announcements from non-profit organizations to help promote local and national charities. Mike has a diverse background with nearly 30 years of television experience in news, production, management, producing and videography. He has worked at television stations in South Dakota, Iowa, and cities in Florida including Fort Myers, Tampa and Miami. He is an award-winning producer of spot news, features, documentaries and a national Addy for a PSA. Giving back to the community is important to Mike and he is a member of several advisory boards including The School of Nursing at Florida Gulf Coast University, The Nations Association and the PACE Center for Girls. Mike graduated Summa Cum Laude from Adelphi University.

Shirley Stone, HNN's National Sales Manager, has over 20 years in the New York advertising industry. She has worked for ad agencies, media departments and started her sales career in magazines - Redbook and Cosmopolitan. In the early 1980's she switched from magazines to the just emerging cable TV industry and was a member of the first MTV sales team. From there she moved on to working for Ted Turner at CNN and then the first New York Director of Sales for The Discovery Channel where she managed a team of account executives and sales support people. Disillusioned with the corporate environment she started a media consulting business and worked on the launch of The Food Network, several Internet companies and By Kids For Kids, a kids innovation company. She holds both a BBA and MBA in marketing, is a graduate of the Communispond Public Speaking Course and is a certified Empowerment Life Coach.

The Healthcare News Network started with less than 10 employees writing, producing, shooting, editing and distributing its programming just one year ago. They now house a team of over 30 employees in three states and will continue to grow along with the success of the nationwide network.

About the Healthcare News Network
The Healthcare News Network, a hospital-exclusive Out-of Home Media Network, was launched in February of 2007 and is based out of Cape Coral, Florida. HNN is the first of its kind to bring customizable, positive healthcare news to each hospital in its network. Currently, HNN is airing in 34 hospitals across Florida with the expansion to 23 states and over 200 hospitals expected to be complete by 2008.

For more information, visit our website: www.healthcarenewsnetwork.com
Or call our office toll free: 800 446 7575

Contact:
Rachel Tramonte
Healthcare News Network
800 446 7575
239 549 4176
rachel @ healthcarenewsnetwork.com
www.healthcarenewsnetwork.com

Press Contact: Rachel Tramonte
Company Name: Healthcare News Network
Phone: 800-446-7575
Website: www.healthcarenewsnetwork.com

# posted by Thuenthkin Anbelos : 3:19 PM  0 Comments

Are you concerned about your memory? Johns Hopkins Health Alerts compares the symptoms of normal memory loss as a result of aging, with memory loss caused by Alzheimer's disease or more serious dementia. Learn how to distinguish between memory loss, mild cognitive impairment, or Alzheimer's disease or other forms of dementia. Also learn two of the other main causes for memory loss.

New York, NY  -  April 9, 2008 -- The recent passing of vibrant actor Charlton Heston from late-stage Alzheimer's disease makes us all stop and think about our own mortality. In particular, it is natural to wonder about your own memory, and what is 'normal' when it comes to memory loss as a result of aging.

Occasional memory lapses, such as forgetting why you walked into a room or having difficulty recalling a person's name, become more common as we approach our 50s and 60s. It's comforting to know that this minor forgetfulness is a normal sign of aging, not a sign of dementia.

But other types of memory loss, such as forgetting appointments or becoming momentarily disoriented in a familiar place, may indicate mild cognitive impairment.

In the most serious form of memory impairment -Alzheimer's and other forms of dementia -- people often find themselves disoriented in time and place and unable to name common objects or recognize once-familiar people.

Here are examples of the types of memory problems common in normal age-related forgetfulness, mild cognitive impairment, and dementia.

Memory Condition -- Normal Age-Related Forgetfulness:
•    Sometimes misplaces keys, eyeglasses, or other items.
•    Momentarily forgets an acquaintance's name.
•    Occasionally has to "search" for a word.
•    Occasionally forgets to run an errand.
•    May forget an event from the distant past.
•    When driving, may momentarily forget where to turn. Quickly orients self.
•    Jokes about memory loss.

Memory Condition -- Mild Cognitive Impairment:
•    Frequently misplaces items.
•    Frequently forgets people's names and is slow to recall them.
•    Finding words becomes more difficult.
•    Begins to forget important events and appointments.
•    May forget more recent events or newly learned information.
•    May temporarily become lost more often.
•    May have trouble understanding and following a map.
•    Worries about memory loss. Family and friends notice the lapses.

Memory Condition -Alzheimer's Disease and Other Forms of Dementia:
•    Forgets what an item is used for or puts it in an inappropriate place.
•    May not remember knowing a person.
•    Begins to lose language skills. May withdraw from social interaction.
•    Loses sense of time. Doesn't know what day it is.
•    Short-term memory is seriously impaired. Has difficulty learning and remembering new information.
•    Becomes easily disoriented or lost in familiar places, sometimes for hours.
•    May have little or no awareness of cognitive problems.

If you are concerned about memory loss in yourself or a loved one, there can be a variety of underlying causes too which can be treated, for example, temporary memory loss due to depression, or certain prescription or over the counter medications. You should discuss such concerns with your doctor.

There are a number of tests your doctor can administer right in the office which can help determine whether it is cognitive impairment or Alzheimer's Sisease or another form of dementia.

FOR MORE INFORMATION
For more information on Memory Loss and Alzheimer's, please visit the Memory topic page at Johns Hopkins Health Alerts:
Johns Hopkins Health Alerts Memory Topic

THE JOHNS HOPKINS GUIDE TO MEMORY LOSS AND AGING
Johns Hopkins Health Alerts has recently published a free special report, "The Johns Hopkins Guide to Memory Loss and Aging." It in you will learn more about the reasons for memory loss as we age, and how to distinguish between Alzheimer's disease and other forms of dementia, versus the normal changes in memory we can all expect as a result of the aging process.
This Special Report also offers 8 Memory Preserving Tips.

For a free copy The Johns Hopkins Guide to Memory Loss and Aging, please visit:
Johns Hopkins Guide to Memory Loss and Aging

Press Contact: JOAN MULLALLY
Company Name: Johns Hopkins Special Reports
Phone: 917-640-4362
Website: http://www.hopkinsreports.com

# posted by Thuenthkin Anbelos : 3:18 PM  0 Comments

FDA Approves Medtronic's Talent Abdominal Stent Graft for Repairing Aortic Aneurysms

Innovative Medical Device Enables Minimally-Invasive Treatment of Potentially Fatal Condition

MINNEAPOLIS--April 16, 2008--Medtronic, Inc. (NYSE: MDT), today announced approval from the U.S. Food and Drug Administration for use of the TalentT Abdominal Stent Graft on the CoilTrac Delivery System, an innovative medical device that expands patient access to a minimally-invasive treatment option for abdominal aortic aneurysms.

Present in an estimated 1.2 million people and responsible for approximately 15,000 annual deaths in the United States, an abdominal aortic aneurysm (AAA) is a dangerous bulge or weakening of the body's main artery that can rupture with fatal consequences if left untreated. Ruptured AAAs are currently the 10th leading cause of death among U.S. men over age 55, with fewer than 20 percent of people surviving a rupture. But early detection through painless ultrasound screening and minimally invasive treatment with a technique called endovascular repair (EVAR) have historically shown a significant improvement in the survival rate for patients of all ages.

"This important milestone demonstrates Medtronic's leadership and commitment to the field of aortic repair," said Katie Szyman, vice president and general manager of the Endovascular Innovations business at Medtronic. "Endovascular interventionalists in the United States now have access to the broadest portfolio of stent grafts for the treatment of their AAA patients. The Talent Abdominal System significantly increases the number of AAA patients who can benefit from minimally-invasive repair. As an alternative to open surgical repair, this device will save the lives of many people affected by abdominal aortic aneurysmal disease."

Expanding Indication for EVAR

The Talent Abdominal Stent Graft System makes endovascular repair (EVAR) accessible to an additional 20 percent of AAA patients, because of its unique proximal aortic neck length requirement of only 10 mm. Consisting of a woven polyester membrane supported by a tubular metal lattice, the device is specifically indicated for endovascular treatment of abdominal aortic aneurysms with or without iliac involvement. The stent graft is available in diameters of up to 36 mm, as well as flared and tapered iliac limbs of 8 mm to 24 mm.

With a 12-year history of strong clinical performance including more than 45,000 implants worldwide, the Talent Abdominal Stent Graft is designed to offer broad patient applicability, suprarenal fixation and positioning accuracy. The stent graft features radiopaque markers for visual guidance during deployment and follow up, and the delivery system uses a single-step release mechanism for smooth deployment and a coiled rod for enhanced trackability and flexibility.

"The Talent Abdominal Stent Graft has provided excellent patient outcomes in clinical practice and in clinical study," said Dr. Michael L. Marin, professor of Vascular Surgery and chairman of the Department of Surgery at The Mount Sinai Medical Center in New York. "In my own experience, with more than 750 successful implants using the Talent System, the performance of this stent graft has been very consistent, and its safety and efficacy have been well characterized through the results of our own clinical trial."

Advantages Over Open Repair

The Medtronic-sponsored clinical study of the Talent Abdominal Stent Graft System enrolled 166 patients at 13 medical centers between February 2002 and April 2003. All 166 patients received a Talent Abdominal Stent Graft; their outcomes were compared to those of 243 patients from the Society of Vascular Surgery (SVS) Surgical Control Group at 30 days and one year post-implant. Dr. Frank Criado, director of Union Memorial Hospital's Endovascular Program in Baltimore, was the principal investigator for the study.

The study demonstrated that the Talent Abdominal Stent Graft well exceeded the SVS Control in freedom from major adverse events at 30 days, with a statistically significant difference between the two groups: Talent, 89.2%; SVS Control, 44.0%. Although patients receiving the Talent Abdominal Stent Graft were older and had a higher baseline rate of co-morbidities, at 30 days post-implant they experienced lower rates of major adverse events compared with subjects treated with open surgery. Importantly, there were no aneurysm ruptures and no conversions to open surgery in the Talent group up to 12 months after device implantation.

"As Talent is already the leading stent graft for endovascular treatment of AAAs outside the United States, its approval by the FDA is a most welcome and exciting development," Dr. Criado said. "AAA patients in this country can now enjoy the benefits of this device, which has been shown in the pivotal clinical trial to have distinct advantages over standard surgical treatment."

In previous studies, EVAR has been shown to be an effective therapy for AAA, with fewer postoperative complications and shorter recovery times than open surgical repair. Results from a U.S. study published recently in The New England Journal of Medicine (Jan. 31, 2008), for example, indicate that perioperative mortality was significantly lower after EVAR than after open repair: 1.2 percent vs. 4.8 percent - a fourfold difference. Similarly, in a landmark study conducted in the United Kingdom and published in The Lancet (Sept. 4, 2004), the 30-day mortality rate for EVAR patients was 1.7 percent compared to 4.7 percent for patients who underwent open repair - a nearly threefold difference.

Although AAAs typically produce no symptoms until rupturing, they can be detected through a simple, painless and inexpensive ultrasound screening, which is offered free-of-charge to new Medicare beneficiaries. If detected before rupturing, AAAs with diameters of more than twice the size of the normal infrarenal aorta are typically treated with either open surgical repair or endovascular repair (EVAR). In contrast to open surgical repair, EVAR involves a minimally invasive procedure in which a stent graft is threaded through the femoral artery in a compressed state on a delivery system and expanded inside the aorta at the site of the aneurysm. Once in place, the stent graft creates a new path for blood flow, reducing pressure on the aneurysm.

As a pioneer of endovascular therapy development, Medtronic has been an innovator and leader in the endovascular stent graft industry for more than a decade, as evidenced by more implants than any other company. Its long history includes more than 130,000 patients treated with stent grafts dating back to 1995. Medtronic currently offers the broadest portfolio of endovascular stent grafts in the industry. These include the AneuRx AAAdvantage® and Talent Abdominal Stent Graft Systems in the United States, and the Talent Abdominal, Talent Thoracic and Valiant® Thoracic Stent Graft Systems outside the United States.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.

Contacts

Medtronic, Inc.
Public Relations
Joe McGrath, 707-591-7367
or
Investor Relations
Jeff Warren, 763-505-2696

# posted by Thuenthkin Anbelos : 3:16 PM  0 Comments

ADAO Applauds the United States Senate for Passing a Resolution to Establish "National Asbestos Awareness Week"

Resolution Furthers Education and Awareness of Asbestos Dangers

Washington, DC . March 6, 2008 --- The Asbestos Disease Awareness Organization (ADAO), an organization dedicated to serving as the voice of asbestos victims, today applauds the United States Senate for passing a resolution that would designate the first week of April as "National Asbestos Awareness Week." In particular, ADAO praises Senator Max Baucus (D-MT) for sponsoring the resolution and additional cosponsors and key supporters of S.RES.108 including: Senator Richard Durbin (D-IL), Senator Dianne Feinstein (D-CA), Senator Johnny Isakson (R-GA), Senator Edward Kennedy (D-MA), Senator Patrick Leahy (D-VT), Senator Patty Murray (D-WA), Senator Harry Reid (D-NV) and Senator Jon Tester (D-MT) for their leadership in this important legislation.

"We are pleased with the passage of this resolution as we approach the day when asbestos is finally banned in the United States," said Dr. Richard Lemen, former Assistant Surgeon General and Co-chairman of the ADAO Science Advisory Board.

"We already know that asbestos exposure causes deadly diseases and cancers that kill Americans on a daily basis. The passage of this resolution will help raise awareness about the dangers of asbestos and move our nation closer to banning the deadly mineral permanently," stated Michael R. Harbut, MD, MPH, FCCP, CoDirector, National Center for Vermiculite and Asbestos-Related Cancers, Karmanos Cancer Institute, Wayne State University.

"The Asbestos Disease Awareness Organization applauds the U.S. Senate and the bi-partisan cosponsors for the passage of this resolution. We cannot bring those back we've lost from exposure to this deadly substance, but we can ensure that our loved ones are not affected by asbestos in the future," said Linda Reinstein, Executive Director and Co-Founder of the Asbestos Disease Awareness Organization.

To recognize National Asbestos Awareness Week, ADAO will hold its fourth annual conference and Remembrance Service at Barbara Ann Karmanos Cancer Institute on March 29-30 in Detroit, Michigan.

About Asbestos Disease Awareness Organization
Asbestos Disease Awareness Organization (ADAO) was founded by asbestos victims and their families in 2004. ADAO seeks to give asbestos victims a united voice to help ensure that their rights are fairly represented and protected, and raise public awareness about the dangers of asbestos exposure and the incurable and often deadly asbestos related diseases. ADAO is funded through voluntary contributions and staffed by volunteers. For more information visit www.asbestosdiseaseawareness.org.

Media Contact:
Doug Larkin
Director of Communications
Asbestos Disease Awareness Organization (ADAO)
Phone: (202) 391-1546
doug@asbestosdiseaseawareness.org

# posted by Thuenthkin Anbelos : 3:15 PM  0 Comments

3M Collaborates with Infectious Disease Research Institute on Vaccine Adjuvants

ST. PAUL, Minn.-- May 01, 2008 --3M Drug Delivery Systems announces the signing of a non-exclusive license agreement with the Infectious Disease Research Institute (IDRI) in support of vaccine research for humanitarian efforts in developing countries. Under the agreement, 3M will donate its patented toll-like receptor (TLR) immune response modifier compounds.

3M's patented TLR immune response modifier compounds, which may be useful as vaccine adjuvants, will be used by IDRI to research new vaccines. Vaccine adjuvants are known to help boost the effectiveness of a vaccine.

"IDRI's vaccine platform has the potential to prevent and treat a number of important diseases in the developing world. By providing our vaccine adjuvant compounds to their vaccines, we are providing a cost-effective way for IDRI to conduct vaccine research," said Dr. Mark Tomai, PhD, Vaccine Business Development, 3M Drug Delivery Systems. "This will help them and us learn more about the potential effectiveness of our vaccine adjuvants. We anticipate this collaboration with IDRI to be the first in many deals around our TLR vaccine adjuvant portfolio."

3M's TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.

"IDRI's access to a 3M compound provides us with a very important tool for our efforts to develop adjuvants to be used in vaccines for diseases of global impact," says Steve Reed, IDRI's Founder and Head of Research. "We are very pleased that 3M has demonstrated this confidence in our organization-and are confident that IDRI's access to the 3M technology will improve our vaccine research and development."

"Our toll-like receptor agonist platform is a major part of our vaccine offering that also includes our Microstructured Transdermal System(a) for needle-free delivery of vaccines. We are at the start of a positive relationship that pairs our unique technology with a critical global need. We look forward to working with IDRI on its vaccine research," said Dr. Steven Wick, Technical Director, 3M Drug Delivery Systems.

About 3M Drug Delivery Systems Immune Response Modifiers

3M Drug Delivery Systems has a portfolio of patent protected toll-like receptor TLR7 and TLR8 agonists that have shown promise as vaccine adjuvants. There are a variety of assets in the portfolio that can be used topically, admixed or in conjugatable form. The lead candidate, resiquimod (TLR7/8 agonist) has shown promising results in a number of animal models and has an extensive toxicology and clinical data package to support further development as a vaccine adjuvant. In addition, 3M offers other TLR7 and TLR8 agonists, some of which can be attached to various proteins that enhance vaccine efficacy in a number of models. As small molecules, 3M's TLR7 and TLR8 agonists offer unique advantages over other TLR agonists with regards to delivery and manufacturing. 3M is actively seeking partners to license these assets on a non-exclusive basis. For more information, or to contact Dr. Tomai, go to www.3m.com/dds.

In addition, 3M Drug Delivery Systems has a variety of immune response modifier compounds that may be useful in oncology and dermatology.

About 3M

A recognized leader in research and development, 3M produces thousands of innovative products for dozens of diverse markets. 3M's core strength is applying its more than 40 distinct technology platforms - often in combination - to a wide array of customer needs. With $24 billion in sales, 3M employs 75,000 people worldwide and has operations in more than 60 countries.

About IDRI

IDRI is a non-profit organization committed to developing technologies to treat "neglected" diseases that place a significant burden on those living in the developing world. IDRI achieves its mission by working closely with industry, universities, and hospitals in developed and developing countries, government and private funding agencies, the Bill and Melinda Gates Foundation as well as the World Health Organization. For more information, go to www.idri.org.

(a)3M Microstructured Transdermal System (MTS) is a state-of-the-art solid microneedle system for transcutaneous or intra-dermal drug delivery. MTS bypasses the barrier properties of the stratum corneum and provides a means to deliver a wide variety of molecules that ordinarily would not penetrate the skin, including vaccines. MTS enhances the efficacy of vaccines by targeting the antigen presenting cells within the skin, thereby improving delivery efficiency and reducing dose requirements. MTS is a painless, easy-to-use system with the potential to greatly improve the delivery of vaccines.
Contacts

3M
Stephanie Sanderson, 651-733-8588
sjsanderson@mmm.com

# posted by Thuenthkin Anbelos : 3:15 PM  0 Comments

Major Sudden Cardiac Arrest Risk Stratification Trials Unveiled

Medtronic-Supported Research Efforts Commencing to Better Determine Which At-Risk Patients - Inside and Outside of Currently Indicated Populations - May Benefit Most from ICD Therapy

MINNEAPOLIS & SAN FRANCISCO-- May 14, 2008 --Medtronic, Inc. (NYSE: MDT), along with several partners, today announced details of several major clinical trials aimed at developing and validating new and innovative risk stratification tools to predict which post-myocardial infarction (MI, or heart attack) patients are at greatest risk of Sudden Cardiac Arrest (SCA). Medtronic's industry-leading research efforts aim to further advance the base of clinical evidence for implanted cardiac device therapies to ensure those patients at greatest risk of SCA are protected.

"We are on the cusp of new discoveries in clinical cardiology. These trials will utilize advanced innovations in technology and research, spanning novel diagnostics to genomics," said David M. Steinhaus, M.D., vice president and medical director of the Cardiac Rhythm Disease Management business at Medtronic. "Medtronic is proud to have partnered with leading researchers worldwide to apply these scientific innovations in an effort to better understand which patients may benefit from implantable medical therapies."

About Medtronic-Supported Risk Stratification Research Trials

    * VEST / PREDICTS (The Vest Prevention of Early Sudden Death Trial / The Prediction of ICD Therapies Study), is a multicenter, randomized controlled trial designed to test a strategy to reduce the early post-MI sudden cardiac arrest risk, followed by an observational cohort study to develop and validate a tool to determine which patients will benefit most from an ICD two months post-MI.

The VEST portion of the study will test the hypothesis that a non-invasive, wearable automatic defibrillator vest will reduce overall mortality in the first 60 days following an MI in patients with LVEF ?35 percent. The PREDICTS portion of the study aims to develop and validate a tool that predicts the occurrence of spontaneous "treatable" ventricular arrhythmias up to five years post-MI, and identify high-risk patients in whom an ICD would be most cost-effective. Study participants will receive either an ICD or Medtronic Reveal® DX insertable cardiac monitor (ICM) to ascertain data on ICD-treatable arrhythmic events.

VEST / PREDICTS is part of a National Institutes of Health (NIH) grant awarded to the University of California-San Francisco (UCSF) and is co-funded by Medtronic, GE Healthcare, and Zoll. It will involve up to 60 centers and more than 4,500 patients in the United States, Canada and Europe.

"The VEST / PREDICTS study is intended to address the two key deficiencies in our current post-MI treatment strategy, which include 1) the untreated high sudden death rate in the early post-MI period and 2) the non-specific nature of ejection fraction to predict spontaneous ventricular arrhythmias and ICD shocks," said Jeff Olgin, M.D., principal investigator for VEST / PREDICTS, and chief of cardiac electrophysiology and professor of medicine at UCSF. "This important study will define a clear pathway to identify those patients who benefit most from ICDs."

    * The objective of Medtronic's GAME (Genetic Arrhythmia Markers for Early Detection) trial is to determine if genetic markers can be used to identify individuals with an increased susceptibility to SCA. Involving 1,000 patients at more than 30 sites in the 48 contiguous United States, GAME will study cardiac events retrospectively to potentially develop a genetic risk scoring system to determine which patients would benefit from an ICD. The first patient enrollment in GAME recently took place at Arkansas Cardiology Clinic in Little Rock, Ark.

"We are about to enter a new era of medicine, one in which so much will eventually be individualized, including prevention and therapy," said Eric Topol, M.D., principal investigator of the GAME trial and chief academic officer at Scripps Health in San Diego. "Genomics has already had a major impact on the treatment of cancer and many other diseases. Now we're looking at genomics of patients with arrhythmias as a way to more precisely treat this important type of heart disease."

    * Also underway is the Medtronic-supported DISCOVERY (Diagnostic Data Influence on Disease Management and Relation of Genetic Polymorphisms to Ventricular Tachyarrhythmias in ICD Patients) trial, involving nearly 1,300 patients at approximately 80 centers in Europe. DISCOVERY is a non-randomized, prospective, multicenter study and is composed of two parts. The first is double-blinded and collects data on genetic polymorphisms and potential prognostic of ventricular and atrial tachyarrhythmias. The second part evaluates the influence of dual chamber ICD-based diagnostic information on long-term patient management and treatment.

Further, Medtronic is committed to ongoing study of Microvolt T-Wave Alternans (MTWA) and other risk markers that will further advance the understanding of how to better identify patients at risk for SCA. MTWA is being studied in the MASTER trial, of which data has previously been presented at the American Heart Association's Scientific Sessions 2007 and American College of Cardiology's Scientific Sessions 2008, and will be presented at Heart Rhythm 2008, the Heart Rhythm Society's 29th Annual Scientific Sessions. Medtronic will continue to explore the potential of MTWA, as evidenced in these aforementioned risk stratification studies.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Notes to editors: To arrange interviews on VEST/PREDICTS with representatives from the University of California-San Francisco, please contact Corinna Kaarlela at 415-476-2557; or GE, contact Corey Miller at 414-469-5499 (cell) or Corey.Miller@ge.com

VEST/PREDICTS disclaimer: The information stated above was prepared by Medtronic Inc. to report research strategies and reflects solely the opinion of Medtronic. Nothing in this statement shall be construed to imply any support or endorsement of Medtronic or any of its products by the Regents of the University of California, its officers, agents and employees.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.

Contacts

Medtronic, Inc.
Public Relations:
Tracy McNulty, 763-526-2492
On-site at HRS: 612-819-2190
or
Investor Relations:
Jeff Warren, 763-505-2696
On-site at HRS: 612-819-7630

# posted by Thuenthkin Anbelos : 3:14 PM  0 Comments